Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells

Payne, Kyle K.; Keim, Rebecca; Graham, Lisa; Idowu, Michael O.; Wan, Wen; Wang, Xiangyang; Toor, Amir A.; Bear, Harry D.; Manjili, Masoud H.

doi:10.1189/jlb.5a1215-580r

Cited by 43 publications

(54 citation statements)

References 22 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have also reported that the use of Aza combined with the immune modulatory lenalidomide induced the expression of CTAs within tumor cells, and generated CTA-specific immune responses in patients with multiple myeloma [64]. Similar results were observed in a mouse model of experimental metastatic breast cancer [65]. Therefore, Dec is an attractive candidate as a neoadjuvant immune modulator when combined with immunotherapy.…”

Section: Epigenetic Targeting Of Tumor Cells For Immune Modulationmentioning

confidence: 62%

See 1 more Smart Citation

Conditioning neoadjuvant therapies for improved immunotherapy of cancer

Benson

Manjili

Habibi

et al. 2017

Biochemical Pharmacology

Self Cite

View full text Add to dashboard Cite

Recent advances in the treatment of melanoma and non-small cell lung cancer (NSCLC) by combining conventional therapies with anti-PD1/PD-L1 immunotherapies, have renewed interests in immunotherapy of cancer. The emerging concept of conventional cancer therapies combined with immunotherapy differs from the classical concept in that it is not simply taking advantage of their additive anti-tumor effects, but it is to use certain therapeutic regimens to condition the tumor microenvironment for optimal response to immunotherapy. To this end, low dose immunogenic chemotherapies, epigenetic modulators and inhibitors of cell cycle progression are potential candidates for rendering tumors highly responsive to immunotherapy. Next generation immunotherapeutics are therefore predicted to be highly effective against cancer, when they are used following appropriate immune modulatory compounds or targeted delivery of tumor cell cycle inhibitors using nanotechnology.

show abstract

Section: Epigenetic Targeting Of Tumor Cells For Immune Modulationmentioning

confidence: 62%

“…It has been reported that dormant tumor cells, while become refractory to chemotherapy, remain susceptible to immunotherapy [65]. Therefore, the next generation immunotherapeutics are expected to be highly effective against cancer, when combined immune modulatory compounds.…”

Section: Control Of Cell Cycle Progression Prior To Immunotherapymentioning

confidence: 99%

Conditioning neoadjuvant therapies for improved immunotherapy of cancer

Benson

Manjili

Habibi

et al. 2017

Biochemical Pharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Examination of genetic background and intercellular signaling may unveil regulatory biomarkers that regard GOQ-2 and GOQ-3. Tumor invasion is variably dynamic and thought to occur by EMT processes in some contexts [204,[219][220][221][222][223]. However, the EMT is not the only program for tumor invasion.…”

Section: Molecular Connections Between Lc and Pcmentioning

confidence: 99%

“…Genetic background across the tumor-stromal axis is the blueprint for cancer behavior [219,251,292]. Inquiries might include: pleiotropic pathways, genomic reconfigurations (e.g., aneuploidy, copy number variations, microinsertions, microdeletions, and translocations), genetic mutations (e.g., promoter, intronic, exonic, and splicing mutations), epigenetic alterations (e.g., de-, hyper-, and hypo-methylation, and deacetylation), epistatic genes and their interactions, diversified miR expression, EMT and non-EMT drivers of tumor invasion, autophagy and metabolism, ECM interactions, exosome-content dispersion, inflammatory mediators, stromal and ECM mediators, and angiogenic and lymphangiogenic mediators.…”

Section: Pan-cancer Analysismentioning

confidence: 99%

The Molecular Connections between Lung and Pancreatic Cancer Metastases: are we not seeing the Forest for the Trees?

Wilson¹

2017

JCPCR

View full text Add to dashboard Cite

Metastases to the pancreas are rare at 1-2%. Among primaries metastasizing to the pancreas, lung cancer (LC) is frequently the culprit. Metastases to the lung from pancreatic cancer (PC) are significantly more common at about 45%, presenting striking differences in cancer behavior. There are conflicting reports regarding cancerogenicity and metastatic incidence between the lung and pancreas. Therefore, this review takes a fresh look at lung and pancreatic cancer behavior. Secondary metastases to the lung and pancreas are often indistinguishable from LC and PC primaries, and the seed and soil hypothesis is not always congruous with clinical interpretation of disease course. Sometimes single "seed" dissemination is thought to occur at the preneoplastic stage without any evidence of tumor invasion. Metastatic growth may become dormant, manifesting years later as cancer of unknown primary (CUP). Interestingly, CUPs are discovered to originate most frequently from LC and PC primaries at autopsy. The lung and pancreas are morphologically related through endoderm-level morphogenesis. The molecular basis of cancer regularity between them involves developmental signaling pathways including HEDGEHOG, NOTCH, WNT, and CXCL12/CXCR4, an evolving genetic background, and regulatory tumor-stromal interactions. Perhaps biomarkers that explain the regularity between them have been documented -as we peruse the bioscience literature for information, we may be reading through viable biomarkers and solutions and not seeing the forest for the trees. On the other hand, perhaps more research is warranted to explain cancer behavior between the lung and pancreas. Observations in this review provide a framework on which to extract clues for future work regarding organspecific metastasis between the lung and pancreas.

show abstract

“…Masoud Manjili of VCU Massey Cancer Center is a tumor immunologist whose research program is focused on immunotherapy of breast cancer and targeting tumor dormancy while overcoming immune suppressor cells (Manjili, 2014;Payne et al, 2016). In their review, Manjili and Butler discuss the poorly understood concept of tumor cell dormancy in the context of immune-mediated maintenance, as well as escape and subsequent recurrence.…”

Section: Immune Regulatory Function Of Tregsmentioning

confidence: 99%